Skip to content Skip to sidebar Skip to footer

Healthcare Stocks

The Mayo Clinic will use 4DX’s CT:VQ and investors are thrilled

Another day, another piece of good news from 4DX Medical (ASX:4DX), today news the Mayo Clinic would be employing the company's technology. Mayo is not the first place where CT:VQ has been deployed, but is easily the highest profile. And investors agree. What are the Best ASX Stocks to invest in right now? Check our buy/sell…

ByNick SundichMarch 25, 2026

The Impact of The Iran War Extends Beyond Oil, And this ASX Company is the Poster Child for It!

It is easy to think the Impact of The Iran War is simply businesses in the oil space or that use oil in their operations (for instance freight businesses). Or by extension, companies in the 'consumer discretionary' space that find due to higher energy prices (and interest rates), that their goods are more discretionary than…

ByNick SundichMarch 25, 2026

Is Echo IQ (ASX:EIQ) a Buy? Mayo Clinic Deal and ASX Index Entry Signal a Major Turning Point

Echo IQ Gains on Mayo Deal and FDA Filing Echo IQ (ASX: EIQ) surged 17% on Tuesday on the back of two catalysts arriving at once. The company has joined the Mayo Clinic Platform's Solutions Studio program, providing access to Mayo's own network and over 80 external partner hospitals, and the stock has been added…

ByUjjwal MaheshwariMarch 25, 2026

Rhythm Biosciences’ ColoSTAT has been commercialised and the roll out will ramp up fast!

Rhythm Biosciences' colorectal cancer test ColoSTAT is officially on the market and has made its first sale. In our view, this could mark the beginning of a major few years for this company. What are the Best ASX Stocks to invest in right now? Check our buy/sell tips [sg_popup id="23914" event="click"][/sg_popup] ColoSTAT is commercialised, albeit not as investors…

ByNick SundichMarch 18, 2026

T-Cell Lymphoma is a very deadly cancer, but this ASX stock has a treatment in a Phase 2 trial!

Prescient Therapeutics' (ASX:PTX) trial of PTX-100 against T-Cell Lymphoma is well and truly underway now with 8 out of 16 trial sites set up. This significant milestone provides significant hope to sufferers of this disease as well as to the company's investors. What are the Best ASX Biotech Stocks to invest in right now? Check our…

ByNick SundichMarch 17, 2026

Same Theme, Better Choices: Here Are 5 ASX Stocks Not To Buy, And 5 To Buy Instead!

It is easy to think of ASX Stocks that are a compelling case to buy, but tougher to think of ASX Stocks Not To Buy. Often, people are lured into companies because they represent compelling thematic right now: surging gold prices, copper's electrification boom, resilient healthcare demand, and a quick-service restaurant sector that keeps growing. But not…

ByNick SundichMarch 17, 2026

Tetratherix (ASX: TTX) Surges 22% After Signing US$30 Million GLP-1 Deal: Is TTX a Buy Right Now?

Tetratherix jumps on new US GLP-1 deal Tetratherix (ASX: TTX) surged 22% on Monday after signing an exclusive deal with US consumer health company Superpower Health to develop a new precision medicine franchise. The agreement is immediately revenue-generating, which is a meaningful shift for a company that has not yet recorded commercial product sales. Under…

ByUjjwal MaheshwariMarch 17, 2026

Telix (ASX:TLX) Pixclara NDA Resubmitted, The FDA Clock Restarts

Pixclara Back With the FDA Telix has resubmitted its NDA to the FDA for Pixclala, its PET imaging agent for recurrent or progressive glioma, a common type of brain tumour. Pixclara is a targeted amino acid PET scan designed to help distinguish true tumour recurrence from treatment-related changes in adult patients. That is a real clinical…

ByCharlie YouldenMarch 16, 2026

Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!

There are plenty of ASX Biotech Targets that major pharmaceutical companies wanting to minimise the impact of the Patent Cliff could look at. For those who don't know what the patent cliff is, it is is one of the most consequential forces in global pharmaceuticals. The concept of a big pharma's drug losing exclusivity and having…

ByNick SundichMarch 16, 2026

Immutep’s Phase 3 trial for Efti has gotten the chop and shares plunge >90%! What now for investors?

After nearly a week in suspense, Immutep (ASX:IMM) confirmed news about Efti that its investors did not want to hear, and arguably feared more and more as the week with trading suspended went on. Namely, its most advanced clinical trial for Efti is all over red rover! While it is not the end of the company,…

ByNick SundichMarch 13, 2026

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

The Mayo Clinic will use 4DX’s CT:VQ and investors are thrilled

The Impact of The Iran War Extends Beyond Oil, And this ASX Company is the Poster Child for It!

Is Echo IQ (ASX:EIQ) a Buy? Mayo Clinic Deal and ASX Index Entry Signal a Major Turning Point

Rhythm Biosciences’ ColoSTAT has been commercialised and the roll out will ramp up fast!

T-Cell Lymphoma is a very deadly cancer, but this ASX stock has a treatment in a Phase 2 trial!

Same Theme, Better Choices: Here Are 5 ASX Stocks Not To Buy, And 5 To Buy Instead!

Tetratherix (ASX: TTX) Surges 22% After Signing US$30 Million GLP-1 Deal: Is TTX a Buy Right Now?

Telix (ASX:TLX) Pixclara NDA Resubmitted, The FDA Clock Restarts

Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!

Immutep’s Phase 3 trial for Efti has gotten the chop and shares plunge >90%! What now for investors?

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Add Your Heading Text Here